Trial Profile
German-Austrian Register to Evaluate the Short and Long-term Safety and Therapy Outcomes of the ABSORB Everolimus-eluting Bioresorbable Vascular Scaffold System in Patients With Coronary Artery Stenosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Adverse reactions
- Acronyms GABI-R
- 31 Mar 2022 Status changed from active, no longer recruiting to completed.
- 01 Oct 2021 Results assessing two-year outcomes in patients with ACS and patients treated for stable CAD published in the Catheterization and Cardiovascular Interventions
- 01 Jul 2021 Planned End Date changed from 1 Mar 2021 to 30 Oct 2021.